Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
cusatuzumab (ARGX-110)
i
Other names:
ARGX-110, ARGX 110, JNJ‑74494550, JNJ-4550, OV-1001
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(2)
News
Trials
Company:
OncoVerity, argenx
Drug class:
CD70 inhibitor
Related drugs:
‹
ex-vivo autologous dendritic cells vaccine (4)
CAT-248 (1)
IMM40H (0)
MP0533 (0)
PF-08046040 (0)
dualCAR-NK19/70 (0)
mono TRuC-T CD70 cell therapy (0)
SGN70 (0)
ex-vivo autologous dendritic cells vaccine (4)
CAT-248 (1)
IMM40H (0)
MP0533 (0)
PF-08046040 (0)
dualCAR-NK19/70 (0)
mono TRuC-T CD70 cell therapy (0)
SGN70 (0)
›
Associations
(2)
News
Trials
VERI cancer hierarchy
Reset Filters
CD70 expression
Cutaneous T-cell Lymphoma
CD70 expression
Cutaneous T-cell Lymphoma
ARGX-110
Sensitive: C3 – Early Trials
ARGX-110
Sensitive
:
C3
ARGX-110
Sensitive: C3 – Early Trials
ARGX-110
Sensitive
:
C3
CD70 expression
Acute Myelogenous Leukemia
CD70 expression
Acute Myelogenous Leukemia
venetoclax + ARGX-110
Sensitive: D – Preclinical
venetoclax + ARGX-110
Sensitive
:
D
venetoclax + ARGX-110
Sensitive: D – Preclinical
venetoclax + ARGX-110
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login